Cancer researcher and break-through drug developer Geoffrey Weiss recently was appointed the University Medical Center's newest chief of hematology-oncology and deputy director of the cancer center.
Weiss previously conducted research at the University of Texas, where he developed the cancer fighting drug interleukin-2, which was approved by the Food and Drug Administration in 1993.
Interleukin-2, used primarily to combat kidney and skin cancer, results in remission among 20 percent of the patients who use it.
Weiss told the Daily Progress that in his new role at the University, he plans to develop targeted therapies, drugs that work to destroy altered cancer-causing cell proteins.
Weiss said he also plans to hire nine new researchers within the next five years and earn the University's Medical Center a top-10 ranking for cancer research.
Read More
Senior VP for Operations Colette Sheehy looks back at her career at the University
By Brandon Kile | 13 hours agoSheehy’s role involved overseeing the work of around 2,500 University employees, including custodians, architects and engineers.
Will the Faculty Senate’s no-confidence vote impact the U.Va. Board of Visitors?
By Brandon Kile | YesterdayIn many cases, a no-confidence vote may soon be followed by steps taken to remove the leadership that may be acting against the wishes of a community.
Two senior U.Va. Health leaders quietly take new jobs without formal announcement
By Ford McCracken | 2 days agoKibbe’s departure marks the end of an ongoing battle between U.Va. Health employees and their senior leadership.
